# Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis

> **NCT01395316** · PHASE4 · COMPLETED · sponsor: **University of Chicago** · enrollment: 8 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Alemtuzumab

## Key facts

- **NCT ID:** NCT01395316
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2015-10
- **Final completion:** 2017-07
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2018-12-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01395316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01395316, "Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT01395316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*